ArticleHIV medicine2026
Cannabis use, microbial diversity and Dialister abundance in older adults with HIV: A cross-sectional study.
Article in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cannabis use by people with HIV is associated with an anti-inflammatory immunometabolic phenotype in monocyte-derived macrophages.Journal of neuroinflammation · 2026Article
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
objectivesPeople with HIV frequently experience gastrointestinal symptoms linked to dysbiosis, impaired mucosal barrier integrity and persistent immune activation. Cannabis is widely used for symptom management by people with HIV, but its effects on the gut microbiome are unclear.
methodsWe conducted a cross-sectional analysis of 63 people with HIV (mean age 59.4 years; 71.4% Black or Hispanic) enrolled in the Marijuana Associated Planning and Long-term Effects study and its microbiome and Alzheimer's substudies, which included participants with and without mild cognitive impairment (MCI). Participants provided faecal samples for 16S rRNA sequencing. Cannabis use was quantified using a validated Timeline Followback. Alpha diversity was estimated using the Shannon index, beta diversity with Bray-Curtis dissimilarity and permutational multivariate analysis of variance (PERMANOVA), and genus-level abundance using the IFAA method. All models were adjusted for age, sex and education.
resultsHigher cannabis consumption showed a statistically significant association with reduced alpha diversity (β = -0.062 per 50-mg Tetrahydrocannabinol (THC) per use-day; 95% confidence interval [CI]: -0.12 to -0.004; p = 0.038). No statistically significant differences in beta diversity were observed between high and low-to-no groups (p = 0.35). At the genus level, Dialister abundance showed a statistically significant dose-dependent association with cannabis use, with a 14.4% reduction in abundance per 50-mg increase in THC per use-day (q = 0.034).
conclusionCannabis consumption in older people with HIV, including those with and without MCI, was associated with lower microbial diversity and reduced Dialister abundance, a taxon with dual roles in mucosal integrity and gastrointestinal symptom modulation. Reduced alpha diversity and Dialister depletion are notable given links to impaired mucosal barrier integrity, microbial translocation and systemic immune activation in HIV. These findings suggest cannabis may modify HIV-associated dysbiosis, warranting further longitudinal studies to disentangle symptomatic benefits from long-term impacts on mucosal health and systemic inflammation.
Indexed as
Identifiers
41431145What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.